First Patient Dosing

Text body: Verrica Pharmaceuticals Inc. (VRCA) announced the dosing of the first U.S. patient in its global Phase 3 program evaluating YCANTH (VP-102) for the treatment of common warts. The COVE-3 study will enroll patients in both the U.S. and Japan, while the COVE-2 study is enrolling only U.S. patients. Torii Pharmaceutical, Verrica's Japanese development partner, also announced dosing of the first Japanese patient in this trial.